Trademark: 90750624
Word
ZENBEXUS
Status
Pending
Status Code
732
Status Date
Friday, April 5, 2024
Serial Number
90750624
Mark Type
5000
Filing Date
Wednesday, June 2, 2021
Published for Opposition
Tuesday, September 6, 2022

Trademark Owner History
Celgene Corporation - Owner At Publication

Classifications
5 Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical and biological preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders, and monoclonal antibodies for medical use
The mark consists of the word ZENBEXUS in blue stylized font except for a red and yellow stylized "x".
The color(s) blue, red and yellow is/are claimed as a feature of the mark.

Trademark Events
Apr 6, 2024
Notice Of Approval Of Extension Request E-Mailed
Apr 5, 2024
Sou Extension 3 Granted
Apr 5, 2024
Sou Extension 3 Filed
Apr 5, 2024
Sou Teas Extension Received
Oct 14, 2023
Notice Of Approval Of Extension Request E-Mailed
Oct 12, 2023
Sou Extension 2 Granted
Oct 12, 2023
Sou Extension 2 Filed
Oct 12, 2023
Sou Teas Extension Received
Apr 26, 2023
Notice Of Approval Of Extension Request E-Mailed
Apr 24, 2023
Sou Extension 1 Granted
Apr 24, 2023
Sou Extension 1 Filed
Apr 24, 2023
Sou Teas Extension Received
Nov 1, 2022
Noa E-Mailed - Sou Required From Applicant
Sep 6, 2022
Official Gazette Publication Confirmation E-Mailed
Sep 6, 2022
Published For Opposition
Aug 17, 2022
Notification Of Notice Of Publication E-Mailed
Jul 30, 2022
Approved For Pub - Principal Register
Jul 29, 2022
Examiner's Amendment Entered
Jul 29, 2022
Notification Of Examiners Amendment E-Mailed
Jul 29, 2022
Examiners Amendment E-Mailed
Jul 29, 2022
Examiners Amendment -Written
Jul 18, 2022
Teas/Email Correspondence Entered
Jul 18, 2022
Correspondence Received In Law Office
Jul 18, 2022
Teas Response To Office Action Received
Jan 27, 2022
Notification Of Non-Final Action E-Mailed
Jan 27, 2022
Non-Final Action E-Mailed
Jan 27, 2022
Non-Final Action Written
Jan 20, 2022
Assigned To Examiner
Aug 25, 2021
New Application Office Supplied Data Entered
Jun 5, 2021
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24